Want to see CNSY full AI Analyst Report?
CNSY Stock Chart & Stats
$3.08
-$0.02(-0.52%)
At close: 4:00 PM EDT
$3.08
-$0.02(-0.52%)
Day’s Range― - ―
52-Week Range$1.86 - $23.44
Previous CloseN/A
VolumeN/A
Average Volume (3M)84.07K
Market Cap
$15.10M
Enterprise Value$21.60
Total Cash (Recent Filing)$8.59M
Total Debt (Recent Filing)$44.00K
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Oct 15, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1033.41
Shares Outstanding7,589,774
10 Day Avg. Volume110,878
30 Day Avg. Volume84,067
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.15
Price to Sales (P/S)2.42
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$46.50Price Target Upside1409.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.39
Revenue Forecast (FY)$6.72M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet LeverageVery low current leverage gives Cerenome greater balance-sheet flexibility than in prior periods and reduces immediate debt-service pressure. The improvement in equity and limited debt may help the company pursue development and commercialization while relying less on conventional borrowing.
Strong Gross Profit MarginA gross margin near 93% indicates that the underlying assay economics can retain substantial revenue after direct costs. If CNSide revenue scales, this margin profile could support operating leverage and improve the path toward breakeven, although current expenses remain too high.
Financing Extends Commercial RunwayThe new financing provides capital to fund CNSide commercial expansion and continued CNS oncology platform development over a multi-year period. Greater runway reduces near-term funding pressure and gives management more time to convert the platform into recurring commercial revenue.
Bears Say
Sustained Cash BurnPersistent operating and free-cash-flow deficits show that the business currently consumes substantial capital rather than funding itself. Continued cash burn increases dependence on financing and can limit strategic flexibility if commercialization does not improve cash generation over the next several quarters.
Declining And Volatile RevenueSmall, volatile, and recently declining revenue provides a weak base from which to absorb the company’s research and operating costs. Without a durable return to growth, Cerenome may struggle to achieve scale, strengthen recurring commercial economics, or reduce its reliance on external capital.
Deep Losses And Capital ErosionLarge recurring losses demonstrate that current revenue is far below the level needed to support the cost structure, including R&D and operating spending. The very negative ROE also indicates continuing erosion of the capital base, leaving profitability dependent on successful future commercialization.
Cerenome News
CNSY FAQ
What was Cerenome’s price range in the past 12 months?
Cerenome lowest stock price was $1.86 and its highest was $23.44 in the past 12 months.
What is Cerenome’s market cap?
Cerenome’s market cap is $15.10M.
When is Cerenome’s upcoming earnings report date?
Cerenome’s upcoming earnings report date is Oct 15, 2026 which is in 17 days.
How were Cerenome’s earnings last quarter?
Cerenome released its earnings results on Aug 14, 2026. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.43.
Is Cerenome overvalued?
According to Wall Street analysts Cerenome’s price is currently Undervalued.
Does Cerenome pay dividends?
Cerenome does not currently pay dividends.
What is Cerenome’s EPS estimate?
Cerenome’s EPS estimate is -0.92.
How many shares outstanding does Cerenome have?
Cerenome has 7,589,774 shares outstanding.
What happened to Cerenome’s price movement after its last earnings report?
Cerenome reported an EPS of -$1.31 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Cerenome?
Currently, no hedge funds are holding shares in CNSY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cerenome
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
CNSY Stock 12 Month Forecast
Average Price Target
$46.50
▲(1409.74% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.80% Insiders
<0.01% Other Institutional Investors
94.81% Public Companies and
Individual Investors



